Belldegrun A, Tsui K H, deKernion J B, Smith R B
Department of Urology, University of California-Los Angeles, Los Angeles, CA 90095-1738, USA.
J Clin Oncol. 1999 Sep;17(9):2868-75. doi: 10.1200/JCO.1999.17.9.2868.
To analyze the experience with nephron-sparing surgery as a treatment modality for renal cell carcinoma (RCC).
Between 1980 and 1997, 146 patients underwent partial nephrectomy at the University of California-Los Angeles Medical Center. A matched group of 125 patients who underwent radical nephrectomy at the same institution between 1986 and 1997 were selected for comparison. Patients were monitored for an average period of 57 months. Patients were staged according to both the 1997 and 1987 tumor-node-metastasis (TNM) staging criteria. Survival data were calculated in terms of both staging criteria.
When comparing cancer-specific survival rates for patients with T1 lesions under both the 1987 and 1997 TNM staging criteria, no statistically significant difference in survival was noted (P =.53), although most of the tumors in our series measured < or = 4 cm. Patients with T2 lesions (1997 TNM) demonstrated a significant decrease in survival (66%) when compared with patients with T1 lesions (100%; P <.001). No statistically significant difference in survival for patients with T1 RCC treated with either radical or partial nephrectomy was noted (P =.219). Survival rates of partial and radical nephrectomies for patients with unilateral T1 RCC and a normal contralateral kidney also were not significantly different (P =.53). In contrast, for patients with lesions greater than T1, survival rates were significantly higher with radical versus partial nephrectomy (P =.001).
Partial nephrectomy has become an effective method of treating T1 RCC lesions as categorized by both the 1987 and the revised 1997 TNM staging criteria. Selected patients with localized unilateral RCC lesions less than 7 cm (ideally, < 4 cm) and a normal contralateral kidney will benefit from partial nephrectomy.
分析保留肾单位手术作为肾细胞癌(RCC)治疗方式的经验。
1980年至1997年间,146例患者在加利福尼亚大学洛杉矶分校医学中心接受了部分肾切除术。选取1986年至1997年间在同一机构接受根治性肾切除术的125例患者作为匹配组进行比较。患者平均随访57个月。根据1997年和1987年肿瘤-淋巴结-转移(TNM)分期标准对患者进行分期。根据两种分期标准计算生存数据。
在1987年和1997年TNM分期标准下,比较T1期病变患者的癌症特异性生存率时,未观察到生存方面的统计学显著差异(P = 0.53),尽管我们系列中的大多数肿瘤直径≤4 cm。与T1期病变患者(100%)相比,T2期病变(1997年TNM)患者的生存率显著降低(66%;P < 0.001)。接受根治性或部分肾切除术的T1期肾细胞癌患者在生存方面未观察到统计学显著差异(P = 0.219)。单侧T1期肾细胞癌且对侧肾脏正常的患者,部分肾切除术和根治性肾切除术的生存率也无显著差异(P = 0.53)。相比之下,对于病变大于T1期的患者,根治性肾切除术的生存率显著高于部分肾切除术(P = 0.001)。
根据1987年和修订后的1997年TNM分期标准,部分肾切除术已成为治疗T1期肾细胞癌病变的有效方法。选定的局限性单侧肾细胞癌病变小于7 cm(理想情况下,<4 cm)且对侧肾脏正常的患者将从部分肾切除术中获益。